Why do professionals disagree? The case of hormone replacement therapy and coronary heart disease prevention

Women and Health

Volumn 38, Issue 3, 2003, Pages 3-18

  Derry, Paula S ^a  

^a NONE   (United States)

Author keywords

Hormone replacement therapy; Menopause; Women's health

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HEALTH PRACTITIONER; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; POSTMENOPAUSE; PRACTICE GUIDELINE; RISK FACTOR;

CONSENSUS; CORONARY DISEASE; DECISION MAKING; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INTERPROFESSIONAL RELATIONS; UNITED STATES; WOMEN'S HEALTH;

EID: 0347600704     PISSN: 03630242     EISSN: None     Source Type: Journal    
DOI: 10.1300/J013v38n03_02     Document Type: Article

References (42)

1. Alexander, K., Newby, L., Hellkamp, A., Harrington, R., Peterson, E., Kopecky, S. et al. (2001). Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. Journal of the American College of Cardiology, 38, 1-7.
2. American Association of Clinical Endocrinologists. (1999). AACE medical guidelines for clinical practice for management of menopause. Endocrine Practice, 5, 355-366.
3. American College of Obstetrics and Gynecology. (1995). ACOG Technical Bulletin Number 210: Health maintenance for the perimenopausal woman. Washington, DC: ACOG.
4. American College of Obstetrics and Gynecology. (1996). Guidelines for women's health care: Primary and preventive care, menopause. Washington, DC: ACOG.
5. American College of Obstetrics and Gynecology. (2001). Statement of the American College of Cardiology on the American Heart Association's position on hormone replacement therapy and cardiovascular disease. July 25, 2001. Retrieved from: www.acog.org/fromme/publications/pressleases/n07-31-01-4.htm.
6. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (1999). ACC/AHA guidelines for the management of patients with acute myocardial infarction. Available at: www.acc.org/clinical/guidelines/nov96/edits/jac1716pVIa.htm.
7. American Heart Association. (1997). AHA medical/scientific statement: Cardiovascular disease in women. Circulation, 96, 2468-2482.
8. American Heart Association/American College of Cardiology. (1999). AHA/ACC scientific statement: Consensus panel statement-guide to preventive cardiology for women. Journal of the American College of Cardiology, 33, 1751-1755.
9. Barrett-Connor, E. (1991). Postmenopausal estrogen and prevention bias. Annals of Internal Medicine, 115, 455-456.
10. Barrett-Connor, E., & Grady, D. (1998). Hormone replacement therapy, heart disease, and other considerations. Annual Review of Public Health, 19, 55-72.
11. Barrett-Connor, E., & Stuenkel, C. (1999). Hormones and heart disease in women: Heart and estrogen/progestin replacement study in perspective. Journal of Clinical Endocrinology and Metabolism, 84, 1848-1853.
12. Bush, T. (1990). The epidemiology of cardiovascular disease in postmenopausal women. Annals of the New York Academy of Sciences, 592, 263-271.
13. Bush, T., Barrett-Connor, E., Cowan, L., Criqui, M., Wallace, R., Suchindran, C. et al. (1987). Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program follow-up study. Circulation, 75, 1102-1109.
14. Clarkson, T. (1998, November). Estrogens, phytoestrogens, SERMs and postmenopausal coronary artery atherosclerosis. Paper presented at the Women's Health Research Symposium, University of Maryland, Baltimore, MD.
15. Col, N., Eckman, M., Karas, R., Pauker, S., Goldberg, R., Ross, E. et al. (1997). Patient-specific decisions about hormone replacement therapy in postmenopausal women. Journal of the American Medical Association, 277, 1140-1147.
16. Derry, P. (2002). Times trends in the HERS secondary prevention trial: Much ado about nothing? Journal of the American Medical Women's Association, 57, 215-216.
17. Grady, D., Rubin, S., Petitti, D., Fox, C., Black, D., Ettinger, B. et al. (1992). Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine, 117, 1016-1037.
18. Grodstein, F., & Stampfer, M. (1998). The cardioprotective effects of estrogens. In J. Studd (Ed.), The management of the menopause (pp. 211-219). New York: Parthenon.
19. Grodstein, F., Stampfer, M., Manson, J., Colditz, G., Willet, W., Rosner, B. et al. (1996). Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New England Journal of Medicine, 335, 453-451.
20. Hamdy, R. (2002). Lessons learned from the Women's Health Initiative. Southern Medical Journal, 95, 951-965.
21. Herrington, D. (1997). Sex hormones and normal cardiovascular physiology in women. In D. Julian & N. Wenger (Eds.), Women and heart disease (pp. 243-264). London: Martin Dunitz.
22. Herrington, D. (1999). The HERS trial results: Paradigms lost? Annals of Internal Medicine, 131, 463-466.
23. Herrington, D., Reboussin, D., Brosnihan, B., Sharp, P., Shumaker. S., & Snyder, T. (2000). Effects of estrogen replacement in the progression of coronary-artery atherosclerosis. New England Journal of Medicine, 343, 522-529.
24. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B. et al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association, 280, 605-613.
25. Hulley, S., Grady D., Vittinghoff, E., Bush, T., Furberg, C., & Riggs, B. (1999). Hormone replacement therapy for secondary prevention of coronary heart disease [Letter]. Journal of the American Medical Association, 281, 797.
26. Jacobs Institute of Women's Health Expert Panel on Menopause Counseling. (2000). Guidelines for counseling women on the management of menopause. Washington, DC: Jacobs Institute.
27. Matthews, K., Kuller, L., Wing, R., Meilahn, E., & Plantinga, P. (1996). Prior to use of estrogen replacement therapy, are users healthier than nonusers? American Journal of Epidemiology, 143, 971-977.
28. Mosca, L. (2001). In reply [to Watts]. Archives of Internal Medicine, 161, 774.
29. Mosca, L., Collins, P., Herrington, D., Mendelsohn, M., Pasternak, R., Robertson, R. et al. (2001). Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation, 104, 499-503.
30. National Committee for Quality Assurance. (2001). HEDIS 2001. Specifications for survey measures (vol. 3). Washington, DC: National Committee for Quality Assurance.
31. National Institutes of Health. (2002). Scientific Workshop on Menopausal Hormone Therapy. Bethesda, MD, October 23-24, 2002.
32. Nabel, E. (2000). Coronary heart disease in women-an ounce of prevention. New England Journal of Medicine, 343, 572-574.
33. Pan, C., & Boat, J. (1999). Hormone replacement therapy for secondary prevention of coronary heart disease. [Letter]. Journal of the American Medical Association, 281, 794.
34. Pettiti, D. (1994). Coronary heart disease and estrogen replacement therapy: Can compliance bias explain the results of observational studies? Annals of Epidemiology, 4, 115-118.
35. Petitti, D. (1998). Hormone replacement therapy and heart disease prevention: Experimentation trumps observation. Journal of the American Medical Association, 260, 650-652.
36. Stampfer, M., Colditz, G., Willett, W., Manson, J., Rosner, B., Speizer, F. et al. (1991). Postmenopausal estrogen therapy and cardiovascular disease. New England Journal of Medicine, 325, 756-762.
37. Tunstall-Pedoe, H. (1998). Myth and paradox of coronary risk and the menopause. Lancet, 351, 1425-1427.
38. Watts, N. (2001). Observational data do not establish cause and effect. Archives of Internal Medicine, 161, 772.
39. Writing Group for the PEPI Trial. (1995). Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. Journal of the American Medical Association, 273, 199-208.
40. Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Journal of the American Medical Association, 288, 321-333.
41. Women's Health Initiative. (2000). WHI HRT update. Retrieved from: www.nhlbi.nih.gov/whi/HRT update2000en.pdf.
42. Women's Health Initiative. (2001). WHI HRT update. Retrieved from: www.nhlbi.nih.gov/whi/HRTUpdate2001.pdf.